Form 4: Blueprint Medicines Director Reports Ownership Changes Post-Sanofi Acquisition

Blueprint Medicines Corporation's Director, Alexis Borisy, reported significant changes in beneficial ownership following the company's acquisition by Sanofi, with all shares, RSUs, and stock options converted into cash and contingent value rights.

Summary

• Blueprint Medicines Corporation (BPMC) was acquired by Sanofi through its subsidiary, Rothko Merger Sub, Inc., as per the Agreement and Plan of Merger.
• The acquisition was completed via a tender offer to acquire all outstanding shares of BPMC common stock.
• Shareholders received $129.00 per share in cash, without interest (the "Cash Offer Price"), plus one contractual contingent value right (CVR) per share.
• The CVRs represent the right to receive additional contingent payments in cash, without interest, upon the achievement of certain milestones.
• On July 17, 2025, the merger became effective, with Purchaser merging into the Issuer, and Blueprint Medicines surviving as an indirect wholly owned subsidiary of Sanofi.
• Director Alexis Borisy's 74,160 shares of common stock were tendered in exchange for the Offer Consideration.
• 3,902 restricted stock units (RSUs) held by Borisy were cancelled and converted into the right to receive the Offer Consideration.
• All outstanding stock options held by Borisy became fully vested, were cancelled, and converted into the right to receive the Cash Offer Price (less the applicable exercise price per share) and one CVR per share.
• Fifty percent of stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, based on the Cash Offer Price (less the applicable exercise price) plus one CVR for each underlying share.
• Following these transactions, Alexis Borisy holds 0 shares of common stock and 0 derivative securities directly.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for former shareholders due to the successful completion of the merger at a significant cash premium ($129.00 per share) and the inclusion of Contingent Value Rights (CVRs) offering potential for additional future payments. This provides immediate liquidity and potential upside, reflecting a successful exit for investors.

Positives

• Shareholders received a substantial cash payment of $129.00 per share, representing a premium for their shares.
• The inclusion of Contingent Value Rights (CVRs) provides potential for additional future payments based on milestone achievements, offering further upside.
• All outstanding restricted stock units (RSUs) and stock options held by the reporting person became fully vested and were converted into the merger consideration, providing liquidity to holders.

Negatives

• Blueprint Medicines Corporation ceased to be an independent publicly traded entity, becoming an indirect wholly owned subsidiary of Sanofi.
• Former shareholders no longer participate in the future growth or equity appreciation of Blueprint Medicines beyond the potential CVR payments.

Risks

• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of specific future milestones, meaning the full value of the offer consideration is not guaranteed and carries performance risk.

Future Outlook

The future outlook for former Blueprint Medicines shareholders includes potential additional cash payments from Contingent Value Rights (CVRs) upon the achievement of certain undisclosed milestones. For the acquired entity, it will operate as an indirect wholly owned subsidiary of Sanofi, integrating into its broader pharmaceutical operations.

Industry Context

This acquisition reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Sanofi acquire innovative smaller firms to expand their pipeline and market presence. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards, particularly for assets with significant future clinical or regulatory milestones.

Comparison to Industry Standards

• The acquisition price of $129.00 per share, coupled with CVRs, is consistent with recent M&A activity in the biotech sector, where premiums are often paid for companies with promising drug pipelines.
• Similar deal structures involving upfront cash payments supplemented by potential future payouts tied to clinical or regulatory milestones have been observed in other significant biotech acquisitions, such as Pfizer's acquisition of Seagen or Merck's acquisition of Acceleron Pharma, indicating a standard approach for valuing pipeline assets.

Stakeholder Impact

• Shareholders: Received $129.00 cash per share plus CVRs, realizing significant value from their investment.
• Employees: Blueprint Medicines employees are now part of Sanofi, with some stock options converted into cash-based awards subject to continued vesting, which may serve as a retention mechanism.
• Company (Blueprint Medicines): Ceased to be an independent public entity, now operating as a subsidiary of Sanofi, impacting its operational autonomy and strategic direction.

Next Steps

• Achievement of specific milestones for the Contingent Value Rights (CVRs) to trigger additional cash payments.
• Integration of Blueprint Medicines Corporation as an indirect wholly owned subsidiary into Sanofi's operations.

Key Dates

Recommendation

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Restricted Stock Units, Beneficial Ownership, SEC Form 4, Pharmaceuticals, Biotechnology